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http://dx.doi.org/10.1016/j.stemcr.2016.05.009SUMMARYIn utero hematopoietic stem/progenitor cell transplantation (IUHSCT) has only been fully successful in the treatment of
congenital immunodeficiency diseases. Using sheep as a large animal model of IUHSCT, we demonstrate that administration of
CD146+CXCL12+VEGFR2+ or CD146+CXCL12+VEGFR2 cells prior to, or in combination with, hematopoietic stem/progenitor cells
(HSC), results in robustCXCL12productionwithin the fetalmarrow environment, and significantly increases the levels of hematopoietic
engraftment.While in the fetal recipient, donor-derivedHSCwere found to residewithin the trabecular bone, the increased expression of
VEGFR2 in the microvasculature of CD146+CXCL12+VEGFR2+ transplanted animals enhanced levels of donor-derived hematopoietic
cells in circulation. These studies provide important insights into IUHSCT biology, and demonstrate the feasibility of enhancing HSC
engraftment to levels that would likely be therapeutic in many candidate diseases for IUHSCT.INTRODUCTION
In utero hematopoietic stem cell transplantation (IUHSCT)
is a clinically viable therapeutic option, which could poten-
tially provide successful treatment for many genetic and
developmental diseases affecting the immune and hemato-
poietic systems (MacKenzie et al., 2015). IUHSCT has safely
been performed for decades in humans and is the only
approach that can promise the birth of a healthy infant
(Muench and Barcena, 2004; Nijagal et al., 2012). To date,
its success has been limited to recipients with severe com-
bined immunodeficiency disorders in which there is a se-
lective advantage of donor cell engraftment/survival over
host cells (Flake et al., 1996; Gotherstrom et al., 2014; Le
Blanc et al., 2005; Touraine et al., 1989; Wengler et al.,
1996). Because IUHSCT must be performed without mye-
loablation or immunosuppression, immunologic barriers
and absence of stress-induced signaling have been consid-
ered as significant contributors to the limited donor HSC
engraftment (Merianos et al., 2009; Nijagal et al., 2011;
Peranteau et al., 2007). Other challenges observed with
IUHSCT result from the unique intricacies of fetal hemato-
poietic stem/progenitor cell (HSC) biology and the fetal
microenvironment. It has been postulated that trans-
planted adult cells could potentially be outcompeted by
endogenous fetal HSC, since the latter are actively cycling
and undergo symmetric self-renewal divisions more effi-
ciently than adult HSC (Bowie et al., 2007). Also, the fetal
microenvironment might not be appropriate to support
engraftment and/or expansion of donor HSC derived
from ontogenically disparate sources, as differences inStem
This is an open access article under the Cmembrane composition and response to cytokines exist be-
tween fetal and adult cells (Arora et al., 2014; Bowie et al.,
2007; Derderian et al., 2014).
MCAM/CD146, within the adult human bone marrow
(BM), is a marker of stromal progenitors/pericytes (Sac-
chetti et al., 2007), which produce stromal cell-derived
factor 1 (SDF-1/CXCL12) and stem cell factor (SCF),
and mediate HSC maintenance/retention (Corselli et al.,
2013; Sugiyama et al., 2006), while VEGFR2/Flk-1 was
shown to specifically define a continuous network of arte-
rioles and sinusoidal endothelial cells within the BM,
which are essential for HSC engraftment and reconstitu-
tion of hematopoiesis (Butler et al., 2010; Hooper et al.,
2009; Kiel et al., 2005). Moreover, in an adult setting,
CD146-expressing subendothelial cells have been shown,
upon transplantation, to be able to transfer the hematopoi-
eticmicroenvironment to heterotopic sites (Sacchetti et al.,
2007).
Here, we investigated whether transplantation of all-
ogeneic adult BM-derived CD146-expressing mesenchy-
mal (CD146+CXCL12+VEGFR2) or endothelial (CD146+
CXCL12+VEGFR2+) cells resulted in stable long-term
contribution/integration into specific fetal BM niches,
and whether administration of these cells, simultaneously
with, or prior to, HSC transplantation, improved levels of
HSC engraftment in an in utero setting. In addition, since
information about the preferential engraftment sites of
adult-derived HSCwithin the fetalmicroenvironment after
IUHSCT is scarce, we also investigated whether and where
donor-derived HSC localized in the fetal BM, and whether
they underwent cell cycling. We also evaluated, in theCell Reports j Vol. 6 j 957–969 j June 14, 2016 j ª 2016 The Authors. 957
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Engraftment Sites of CD146++ and CD146+++ Cells Transduced with an mKate-Expressing Lentivector, and Production of
Endogenous and Donor-Derived SCF and CXCL12/SDF-1 in Transplanted Recipients’ Diaphysis at 2–2.5 Months Post Transplant
(A) Percentage of CD146+++ and CD146++ cells engrafted in diaphysis calculated as described below. *p < 0.05.
(B–H) Representative images from the animals of in (A). (B) Production of SCF (green) by stromal perivascular and vascular cells (left
panel); engrafted CD146++ (mKate+, red) cells localized within the stromal, perivascular, and vascular niches (central panel); production
(legend continued on next page)
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co-transplantation approach, whether cell-cell interact-
ions with CD146+CXCL12+VEGFR2 or CD146+CXCL12+
VEGFR2+ cells played a role in altering the patterns or levels
of engraftment of subsequently transplanted HSC, and
sought to identify the responsible factors. Our results
show that, in a non-myeloablative fetal setting, allogeneic
adult donor HSC engraft within themetaphysis, and prolif-
erate efficiently beside endogenous hematopoietic cells,
while CD146+CXCL12+VEGFR2+and CD146+CXCL12+
VEGFR2 cells integrate in a different anatomic area, the
bone, and/or vasculature of the diaphysis. Mechanistically,
we demonstrate that CD146+CXCL12+VEGFR2+ and
CD146+CXCL12+VEGFR2 cells contribute to robust
CXCL12 production, and that increased expression of
VEGFR2 in the microvasculature of CD146+CXCL12+
VEGFR2+ transplanted animals paralleled enhanced levels
of donor-derived hematopoietic cells in circulation. These
studies provide additional insights into IUHSCT biology,
and demonstrate the feasibility of enhancing donor HSC
engraftment to levels that would likely be therapeutic in
many of the diseases that are candidates for IUHSCT.RESULTS
CD146+CXCL12+VEGFR2 and
CD146+CXCL12+VEGFR2+ Cells Engraft in the
Diaphysis
Fetal sheep recipients were transplanted with CD146++ or
CD146+++ cells 3 days prior to, or simultaneouslywith, HSC
and evaluated at 2–2.5 months post transplant (120–140
gestational days) as described in Experimental Procedures.
Characterization of CD146+CXCL12+VEGFR2 (abbrevi-
ated as CD146++) and CD146+CXCL12+VEGFR2+ (abbre-
viated as CD146+++) cells is provided in Supplemental
Experimental Procedures and Figure S1. We used confocalof SCF by transplanted CD146++ cells (right panel, merged image). (C)
(left panel); engrafted CD146+++ (mKate+, red) cells localized withi
production of SCF by transplanted CD146+++ cells (right panel, merged
transplanted cells. (D) Engrafted CD146++ (mKate+, red) cells and (
SDF-1/CXCL12 localizes primarily to transplanted CD146++ cells and (E
(right panels, merged images). (F and G) Evaluation of metaphysis ar
red) cells, nor (G) CD146+++ (mKate+, red) cells reside within this a
(mKate+, red) cells integrated into vascular structures and expressed
(I) Quantification of the relative percentage of transplanted cells exp
(J) Quantification of the relative percentage of transplanted cells ex
Percentage of cells positive for the different specific markers was calcu
and determining, within these, the number of cells also positive for
periments). Animals were randomly selected from the pool of transpla
DAPI (blue) labels all nuclei. Arrows indicate features enlarged in inse
confocal microscope; for most of the images an Olympus UPlanFLN 403
also used as noted. 603 magnification was used in (C). Confocal ima
projected as 2D images and saved. Detailed characterization of CD14microscopy to determine whether CD146++ or CD146+++
cells are able to durably engraft fetal recipients and to inves-
tigate the spatial distribution of the transplanted (far-red
fluorescent protein [mKate]-expressing [Shcherbo et al.,
2007]) CD146+++ and CD146++ cells within the trabecular
(metaphysis) and cortical (diaphysis) regions.
Regardless of the transplant schedule/regimen, donor-
derived CD146++ cells engrafted at significantly higher
levels than CD146+++ cells (Figure 1A), and both cell popu-
lations localized primarily to the recipient diaphysis
(Figures 1B–1E, central panels). Very few, if any, mKate-ex-
pressing cells were detected in the metaphysis of animals
transplanted with CD146++ (Figure 1F) or CD146+++ (Fig-
ure 1G) cells.
Within the diaphysis, donor-derived CD146++ and
CD146+++ cells integrated into the vascular and perivascu-
lar niches (Sacchetti et al., 2007), and continued to express
CD146 (Figure 1H). In addition, engrafted CD146++ and
CD146+++ cells produced SCF (Figures 1B and 1C; right/
merged panel) and SDF-1/CXCL12 (Figures 1D and 1E;
right/merged panel). Quantification of the relative contri-
bution of transplanted cells to overall production of SCF
and SDF-1/CXCL12 can be seen in Figures 1I and 1J, respec-
tively. CD146+++ and CD146++ cells accounted, respec-
tively, for 48.6% ± 1.0% and 58.8% ± 1.4% of cells positive
for SCF. By contrast, as can be seen in Figures 1D and 1E
(right/merged panel), SDF-1/CXCL12 expression was de-
tected primarily in the areas where transplanted cells lo-
calized. Moreover, CD146+++ cells robustly contributed to
SDF-1/CXCL12 production, such that 93% ± 2.3% of all
SDF-1/CXCL12+ cells were donor derived.
Significant differences were also found with respect to
the localization of the engrafted donor-derived CD146++
and CD146+++ cells (Figures 2A and 2B, respectively;
right/merged panel with transmitted light display to iden-
tify bone structures). CD146++ cells were readily identifiedProduction of SCF (green) by stromal perivascular and vascular cells
n the stromal, perivascular, and vascular niches (central panel);
image). (D and E) Production of diaphyseal SDF-1/CXCL12 (green) by
E) CD146+++ (mKate+, red) cells (central panels); (D) synthesis of
) robust contribution of CD146+++ cells to SDF-1/CXCL12 production
ea demonstrating that neither transplanted (F) CD146++ (mKate+,
rea of the BM. (H) Within the diaphysis, donor-derived CD146+++
CD146 (green).
ressing SCF. *p < 0.05.
pressing SDF-1/CXCL12. *p < 0.05.
lated after counting a total of 1,139 ± 207 DAPI+ nuclei/experiment
a specific marker (n = 3 animals per group, three independent ex-
nted animals with CD146++ cells (n = 11) or CD146+++ cells (n = 7).
ts. Confocal images were acquired with an Olympus Fluoview FV1000
/1.30 oil objective was used; a Plan ApoN 603/1.42 objective was
ges were taken as z stacks with 5–10 slices per image before being
6++ and CD146+++ cells is provided in Figure S1.
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Figure 2. CD146++ Cells Contribute to the Vascular and Bone Niche, while CD146+++ Cells Engrafted Mostly in Perivascular Sites an
Expressed VEGFR2/Flk-1
(A) Representative image of GFP+ donor-derived hematopoietic cells (green; left panel); CD146++ (mKate+, red) cells were present at
significant levels within the osteoblastic layer of the cortical bone (central panel, and right panel with transmitted light display to identify
bone structures, also marked with dotted line); GFP+ donor-derived hematopoietic cells (green) can be seen in clusters in close proximity
to donor-derived CD146++ bone niche cells (mKate+, red; right panel).
(B) Representative image of GFP+ donor-derived hematopoietic cells (green; left panel); CD146+++ cells (mKate+, red) rarely contributed to
bone niches, and localized in perivascular areas (central panel). Transmitted light display (right panel) is included to identify bone
structure, also marked with dotted line; GFP+ donor-derived hematopoietic cells (green) are often found in clusters in close proximity to
CD146+++ vascular niche cells (mKate+, red; right panel).
(C) Quantification of the relative percentage of transplanted cells expressing VEGFR2/Flk-1 Determination of percentage of cells positive
for VEGFR2/Flk-1 was calculated after counting a total of 839 ± 37 DAPI+ nuclei/experiment and determining, within these, the number of
cells also positive for VEGFR2/Flk-1 (n = 3 animals per group). *p < 0.05.
(legend continued on next page)
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Figure 3. GFP+ Hematopoietic Cells
Localize Predominantly to the Metaphysis
and Are Actively Cycling
(A and B) Representative images of GFP+
(green) donor-derived hematopoietic cell
engraftment in the trabecular bone niche of
the metaphysis in animals transplanted with
CD146++ (A) and CD146+++ (B) cells.
(C) Percentage of GFP+ donor-derived he-
matopoietic cells cycling within the meta-
physis, using Ki67, demonstrating that, in
this area, most of the transplanted he-
matopoietic cells (GFP+) were cycling
(Ki67+). Determination of percentage of
cycling cells was accomplished by counting
an average of 727 ± 80.8 DAPI+ nuclei per
experiment, and quantifying the number of
GFP+, Ki67+, and GFP + Ki67+ double-positive
cells; the percentage of cycling donor cells
(GFP+ Ki67+) was then determined after
normalizing to the percentage of engrafted
GFP+ cells (n = 4 animals per group, two in-
dependent experiments).
(D) Representative image of Ki67 staining,
demonstrating that donor GFP+ cells are
cycling.
DAPI (blue) labels all nuclei. Arrows indicate
features enlarged in insets. Confocal images
were acquired with an Olympus FV1200 Spectral laser scanning confocal microscope and an Olympus UPlanFLN 403/1.30 oil objective;
confocal images were taken as z stacks with 5–10 slices per image before being projected as 2D images and saved. See also Figure S2.within cortical bone structures, while CD146+++ rarely
located to bone niches.
We next investigated the contribution of donor-derived
CD146++ andCD146+++ to VEGFR2/Flk-1 production (Fig-
ure 2C). Transplanted CD146+++ cells contributed to the
majority of VEGFR2/Flk-1 expressed within the diaphysis
(Figures 2C and 2D), and their support was significantly
higher than that provided by CD146++ cells (Figures 2C
and 2E).
Donor-Derived Hematopoietic Cells Localize
Primarily to the Trabecular Bone Niche of the
Metaphysis
We next investigated which niches the donor-derived
hematopoietic cells occupied, defined their relationship
with transplanted stromal cell populations, and deter-
mined whether there was a preferential interaction be-
tween donor-derived (GFP+) HSC and donor-derived(D) Robust production of VEGFR2/Flk-1 (green; left panel) by transplan
CD146+++ (red) cells produce the majority of VEGFR2/Flk-1 within the
(E) Production of VEGFR2/Flk-1 (green; left panel) by transplanted
CD146++ cells (mKate+, red) co-express VEGFR2/Flk-1 (right panel).
Arrows indicate features enlarged in insets. Confocal images were ac(mKate+) CD146++ or CD146+++ cells. Regardless of the
cell type used for the combined transplant or the time of
transplant, donor-derived GFP+ hematopoietic cells lo-
calized primarily to the trabecular bone niche of the meta-
physis (Figures 3A and 3B) and were actively cycling, as
determined by Ki67 staining, demonstrating that adult
hematopoietic cells are able to effectively cycle in vivo in
a fetal environment (Figures 3C and 3D).
Co-transplantation of CD146+++ and CD146++ Cells
Affects Hematopoietic Engraftment
The levels of donor-derived (GFP+) HSC engraftment in the
BM are shown in Figure 4. Animals that received HSC
3 days after CD146+++ cell transplant (3+++) had signifi-
cantly higher levels of donor-derived hematopoietic
engraftment (p < 0.05) than those receiving HSC alone
(HSC) or those that received HSC concurrently with
CD146+++ cells (0+++) (Figure 4A). Colony-forming unitted CD146+++ (red) cells (central panel) within diaphysis; engrafted
perivascular niche (right panel).
CD146++ (red) cells (central panel) within the diaphysis; Fewer
DAPI (blue) labels all nuclei.
quired as described in Figure 1.
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Figure 4. Animals Transplanted with
CD146++ and CD146+++ Cells Have Higher
Levels of Donor-Derived GFP+ Hematopoi-
etic Cells
(A) Determination of levels of donor-derived
GFP+ HSC engraftment in the metaphysis
showed that HSC3+CD146+++ animals (n = 3
independent experiments, two animals/
group) had significantly higher levels of
donor-derived (GFP+) HSC engraftment (*p <
0.05) than the HSC (n = 3 independent
experiments, two animals/group) or the
HSC0+CD146+++ group; (n = 3 independent
experiments, three animals/group).
(B) CFU assays performed using freshly
collected BM from transplanted animals
showed that HSC3+CD146+++ animals con-
tained a significantly (*p < 0.05) higher
number of donor-derived (GFP+) CFU than the
other transplant groups (n = 3 animals per
group, except for HSC3+CD146+++ and HSC,
n = 2 animals per group; each with n = 3
technical replicates).
(C) HSC3+CD146++ and HSC0+CD146++ ani-
mals had significantly higher HSC engraftment
(*p < 0.05) than the HSC group (n = 3 ani-
mals/group; three independent experiments).
(D) CFU assays performed using freshly
collected BM from transplanted animals
showed that HSC3+CD146++ animals contained a higher number of donor-derived (GFP+) CFU than the other transplant groups, but
statistical significance was not achieved (n = 3 animals/group; each with n = 3 technical replicates).(CFU) assays, performed using freshly collected BM,
showed that 3+++ animals contained a significantly (p <
0.05) higher number of donor-derived (GFP+) CFU than
the other transplant groups, attesting to the higher clono-
genic potential of the engrafted cells in this group (Fig-
ure 4B). Of note, concurrent transplantation of HSC and
CD146+++ cells (0+++) did not significantly increase the clo-
nogenic potential of the engrafted cells beyond that seen
with HSC alone (Figure 4B).
In the metaphysis of animals that received HSC 3 days
after CD146++ cell transplant (3++) and HSC simulta-
neously with CD146++ cells (0++), the percentage of
donor-derived HSC engraftment was significantly higher
(p < 0.05) than in the group transplanted with HSC alone
(HSC) (Figure 4C). However, no statistical significance
was found between the percentage of donor-derived he-
matopoietic engraftment and clonogenic potential of
engrafted cells in animals that received 3++ and 0++
(Figure 4D).
Analysis of the diaphysis also demonstrated that, in all of
the recipients (Figures 5A and 5B), smaller numbers of
donor-derived GFP+ hematopoietic cells were present in
this region, but localized in clusters in close proximity to962 Stem Cell Reports j Vol. 6 j 957–969 j June 14, 2016mKate+ (donor) niche cells (Figures 5A and 5B; right/
merged panels) in areas close to the vasculature.
In the diaphysis, quantitative analysis of mKate+CD146+
cells in forming vasculature demonstrated that, in this area,
there was a direct correlation between the levels of
donor-derived mKate+CD146+ cells engrafted within the
vasculature and the numbers of donor-derived GFP+ he-
matopoietic cells present in the perivascular areas (defined
as being within a distance of five nuclei from a vessel)
(Figure 5C).
CD146+++ Cells Have a Significant Effect on the Levels
of Donor-Derived Hematopoiesis in Peripheral Blood
We next investigated the impact of transplanting
CD146+++ or CD146++ cells simultaneously with HSC
(0+++ and 0++, respectively), or 3 days prior to HSC (3+++
and 3++, respectively), on the repopulation of peripheral
blood (PB) with donor-derived hematopoiesis. At
2–2.5 months post transplant, the levels of circulating
donor-derived hematopoietic cells were compared between
animals that received HSC, 0+++, 3+++, 0++, and 3++. Flow
cytometric evaluation of GFP+ cells in PB demonstrated
that 3+++ recipients had significantly higher circulating
Figure 5. Smaller Numbers of Donor-Derived GFP+ Hematopoietic Cells Were Present in the Diaphysis, and a Correlation Existed
between the Levels of Donor-Derived CD146+ Cells Engrafted within the Vasculature and the Numbers of Donor-Derived GFP+
Hematopoietic Cells Present in the Perivascular Areas
(A and B) GFP+ hematopoietic cells in the diaphysis of animals transplanted with either (A) CD146++ or (B) CD146+++ cells. GFP+ cells were
found in close proximity to CD146++ or CD146+++ (mKate+, red) cells. DAPI (blue) labels all nuclei. Arrows indicate features enlarged in
insets. Confocal images were acquired as described in Figure 1.
(C) Correlation between the numbers of donor-derived CD146+ cells (red) engrafted within the vasculature and the numbers of donor-
derived GFP+ hematopoietic cells present in the perivascular areas (defined as being within a distance of five nuclei from vessel) (n = 7
animals).
(D) Percentages of circulating donor hematopoietic cells in animals transplanted with different cell populations determined by flow
cytometric analysis (*p < 0.05). n = 3 animals per group and two independent experiments, except for HSC3+CD146+++ and HSC groups
(n = 2 animals per group with two independent experiments).levels of donor cells (p < 0.05) than those receiving HSC
alone, 0+++, 3++, or 0++ (Figure 5D).
Donor-Derived HSC Are Not Detected within the Fetal
Liver of Transplanted Animals
We next performed studies to confirm that donor-derived
hematopoiesis was mainly localized to the BM, and that
the higher levels of donor hematopoietic cells in circula-
tion seen with some of the transplanted groups were not
due to establishment of donor-derived hematopoiesis
within the liver of the fetal recipients. No donor (GFP+) he-
matopoietic cells were detected in the liver of any of the
transplanted animals, regardless of the transplantation
scheme (Figure 6A, left panel), despite the presence of
host/recipient CD45+ cells within this tissue (Figure 6A,right panel). Of note is that, after in utero transplantation,
both donor-derived mKate+ stromal cell populations were
detected at significant levels within the hepatic paren-
chyma (Figures 6B and 6C [central panels], and Figure 6D).
Elevation of SDF-1 levels in PB can mobilize HSC to the
circulation, with a concomitant decrease of HSC within
the BM (Hattori et al., 2003). Because mKate+ CD146+++
and CD146++ stromal cells in the BM produced SDF-1,
we next investigated whether donor-derived stromal cells
contributed to SDF-1 production following engraftment
within the fetal liver. As previously described (Coulomb-
L’Hermin et al., 1999; Kollet et al., 2003), SDF-1+ cells
were present within the hepatic parenchyma, but, in
contrast to what we observed within the BM, very few of
the mKate+ CD146+++ or CD146++ donor cells thatStem Cell Reports j Vol. 6 j 957–969 j June 14, 2016 963
Figure 6. Donor-Derived mKate+ Cells, but Not GFP+ Donor-Derived Hematopoietic Cells, Are Detected within the Fetal Liver of
Transplanted Animals
(A) Regardless of the transplantation scheme, donor-derived (GFP+) hematopoietic cells were not detected in the liver of any of the
transplanted animals, even after staining with an antibody against GFP (left panel), and despite the ability to detect host/recipient CD45+
cells within this tissue (right panel) using an antibody against CD45; mKate+ (red) CD146++ and CD146+++ cells were readily detected.
(B and C) CXCL12/SDF-1+ cells were present within the hepatic parenchyma of transplanted animals (left panels); very few of the donor-
derived (mKate+, red) CD146++ (B) and CD146+++ (C) cells expressed this chemokine.
(D) Percentage of CD146+++ and CD146++ cells engrafted in liver calculated as described below. *p < 0.05.
(E) Quantification of the relative percentage of transplanted cells expressing SDF-1. Determination of percentage of positive cells for the
different markers was calculated after counting a total of 222 ± 18 DAPI+ nuclei/experiment and determining, within these, the number of
cells also positive for the respective markers (n = 3 per group).
DAPI (blue) labels all nuclei. Confocal images were acquired as described in Figure 3.engrafted the liver continued to express this chemokine
(Figures 6B and 6C). A graphical depiction of the relative
contribution of donor-derived CD146+++ and CD146++
cells to overall SDF-1 production within the recipient fetal
liver is shown in Figure 6E.
DISCUSSION
Similarly to unconditioned adult recipients, transplanta-
tion of allogeneic HSC into non-ablated fetal hosts faces
serious challenges. Immunologic barriers posed by the
mother’s immune system (Merianos et al., 2009; Nijagal964 Stem Cell Reports j Vol. 6 j 957–969 j June 14, 2016et al., 2011) and by the emerging innate and adaptive im-
munity of the host (Bhattacharya et al., 2006; De Kleer
et al., 2014; Peranteau et al., 2007; Rechavi et al., 2015;
Renoux et al., 2015; Szepfalusi et al., 2000; Xu et al.,
2004) can lead to graft rejection, or at least significant graft
loss, before donor-specific tolerance is achieved (Peranteau
et al., 2015). For example, in non-irradiated adult animals,
only continuous infusion (Wright et al., 2001) or trans-
plantation of extraordinarily high doses of BM HSC (Rao
et al., 1997) have resulted in hematopoietic chimerism;
such approaches would be challenging to implement in a
fetal setting.
Robust long-term engraftment of adult-derived cells in a
fetal setting also depends upon the ability of adult cells to
effectively compete with endogenous cells for the appro-
priate niches (Bhattacharya et al., 2006; Calvi et al., 2003;
Ding et al., 2012; Greenbaum et al., 2013; Kunisaki et al.,
2013) and the existence of fully functional microenviron-
ments (Jeanblanc et al., 2014) that can support/promote
adult hematopoiesis.
The fetal sheep model (Flake et al., 1986) has proved to be
instrumental in developing strategies for IUHSCT, since it is
outbred and therefore genetically diverse, and parallels hu-
man immune and hematopoietic development; moreover,
data collected in this model were used by Flake et al. (1996)
to design the transplantation approach to achieve the first
clinical cure with IUHSCT. Nevertheless, like any other ani-
mal model, sheep cannot exactly reproduce all the features
of human pregnancy. For instance, probably due to the
type of placentation, ewes donotmodulatematernal immu-
nity towardamore tolerogenicphenotype, and therefore the
role of maternal immunity in fetal transplant rejection
cannot be addressed in this model (Entrican et al., 2015).
Nevertheless, using this model, we demonstrated the
possibility of increasing hematopoietic engraftment after
IUHSCT by the administration of stromal elements (Al-
meida-Porada et al., 1999, 2000). However, we did not char-
acterize which populations within the adult stromal cells
were responsible for the effect, nor didwe address the inter-
action between transplanted HSC and stromal cells or the
long-term fate and localization of the transplanted cell
populations, leaving unanswered the questions of whether
and where within the BM these cells lodged.
In these studies, we show that CD146++ or CD146+++
cells are responsible for the significant increase in the levels
of donor-derived hematopoietic engraftment, and that
CD146++ and CD146+++ cells engrafted long-term, local-
ized almost exclusively within the diaphysis of the fetal
BM, and integrated within the bone and perivascu-
lar niches. By contrast, transplanted CD146++ and
CD146+++ cells did not residewithin themetaphysis of fetal
recipients. Unexpectedly, the vast majority of the trans-
planted HSC, independent of the transplantation
schedule/approach, were found within the metaphysis,
where they were actively cycling, demonstrating that adult
cells can efficiently divide in the fetal microenvironment.
Since our analysis was performed at over 2 months after
IUHSCT, the results obtained reflect an examination of
the localization of the transplanted HSC in the ‘‘steady
state,’’ after durable engraftment took place.
We also show that a direct correlation exists between the
levels of donor-derived CD146++ or CD146+++ cells within
perivascular regions of the diaphysis and the levels of
donor hematopoietic engraftment seen in the vicinity
(within five cell nuclei) of vasculature containing donor-derived niche cells. This finding could suggest that
providing an adult-derived perivascular niche enables
more donor-derived HSC to migrate to or engraft within
the BM. During fetal development, long bones are the pri-
mary site for BM hematopoiesis (Proytcheva, 2013) and,
given that blood flow through the long bones proceeds
mostly from the diaphysis to the metaphysis, the engraft-
ment of CD146++ CD146+++ cells within the diaphysis
and their production of hematopoiesis-supporting chemo-
kines may serve to attract transplanted HSC to the marrow
cavity, fromwhence they are then drawn to themetaphysis
by the active bone remodeling at this stage of development
and by the high hyaluronic acid synthase levels present in
that region (Figure S2, top panel) when compared with the
diaphysis of fetal sheep (Figure S2, lower panel).
These data are in agreement with prior studies demon-
strating that hyaluronan levels play a critical role in deter-
mining the site of HSC lodgment/engraftment following
transplantation (Avigdor et al., 2004; Ellis et al., 2007,
2009, 2011; Nilsson et al., 2003), and thatHSC exhibit pref-
erential engraftment within sites of active bone remo-
deling (Chan et al., 2009).
In the adult, SDF-1/CXCL12 plays a critical role in BM re-
population by circulating CD34+ progenitors (Peled et al.,
1999a, 1999b), and during development, SDF-1 induces
the migration of primitive HSC from the fetal liver to the
BM (Ma et al., 1998) and promotes HSC colonization (Ara
et al., 2003). Likewise, membrane-bound SCF is important
for HSC maintenance (Barker, 1997) and myeloid develop-
ment after transplantation (Takagi et al., 2012). Both
CD146++ and CD146+++ cells expressed, in vitro and after
in vivo engraftment, SDF-1 and SCF. However, our analyses
also showed that SCF is ubiquitously present within the
fetal microenvironment, suggesting that SCF provided by
the transplanted cells is not likely to be responsible for
the observed enhancement in engraftment. By contrast,
BM immunohistochemistry of transplanted animals
showed robust SDF-1/CXCL12 production by transplanted
CD146+++ cells. The production of SDF-1/CXCL12 at the
site of HSC entrance/exit provides a potential explanation
for the increased HSC engraftment seen in the co-trans-
planted animals over those receiving HSC alone.
CD146+++ and CD146++ cells seem to affect HSC engraft-
ment through some additional cell-specific mechanism,
since CD146+++ cells only produced a statistically significant
increase in BM donor hematopoietic engraftment if they
were administered 3 days prior to the HSC. In contrast,
CD146++ cells enhanced BM hematopoietic engraftment
whether theywere administered3daysprior to theHSCgraft
or concomitantly with it. The ability of CD146++, but not
CD146+++, cells to enhance hematopoietic engraftment
when transplanted simultaneously with the HSC, suggests
that the effect of CD146++ cells could be mediated, at leastStem Cell Reports j Vol. 6 j 957–969 j June 14, 2016 965
in part, by their ability to alter the innate and adaptive im-
mune responses (Domev et al., 2014; English et al., 2010;
LeBlancandDavies, 2015;LeBlancetal., 2007),perhapspro-
tecting the transplantedHSC fromthe rudimentary immune
elements present within the fetus at this stage of gestation
(Skopal-Chase et al., 2009).
Our data also show that HSC3+CD146+++ animals exhibit
significantly higher levels of overall hematopoietic cell
engraftment than any other group. In vitro, and after
engraftment, CD146+++ cells strongly expressed VEGFR2
while CD146++ cells did not, suggesting that, even in the
absence of injury to the vascular niche (Hooper et al.,
2009),VEGFR2 seems toplay a role in increasinghematopoi-
etic engraftment in the fetal recipient. This could be due to
VEGFR2’s ability to promote survival of hematopoietic pro-
genitors through the activation of anti-apoptotic pathways
(Larrivee et al., 2003) and/or stimulating the formation of
hematopoietic-supportinghemospheres (Wang et al., 2013).
It is also of note that the data presented here corroborate
reports demonstrating that mesenchymal stromal cells
transplanted in utero contribute to the forming bone,
and could therefore be of clinical benefit for patients with
osteogenesis imperfecta (Gotherstrom et al., 2014). More
importantly, we demonstrate that a substantial fraction of
transplanted stromal cells were found in the liver and never
reached the BM, underscoring the need for defining strate-
gies to increase bone engraftment of mesenchymal cells
after in utero transplantation (Jones et al., 2012; Millard
et al., 2015).
Overall, these studies demonstrate that in a fetal setting,
transplanted HSC locate primarily in the metaphysis,
and that both CD146++ and CD146+++ stromal cells
contribute, long-term, to the different BM niches and in-
fluence hematopoiesis through CXCL12, crucial for suc-
cessful HSC engraftment in a fetal setting. Moreover, we
show the feasibility of using a co-transplantation strategy
that significantly (>10-fold) enhances donor HSC engraft-
ment following IUHSCT. Because stromal cells have been
transplanted safely in fetal recipients, confirmation of
these results in another preclinical model would allow
this straightforward and clinically viable approach to be
used in a clinical setting to achieve levels of hematopoietic
cell engraftment that would likely be therapeutic in many
of the diseases that are candidates for treatment by
IUHSCT.EXPERIMENTAL PROCEDURES
Isolation and Expansion of Sheep BM-Derived Stromal
Cells and Hematopoietic Stem/Progenitor Cells
Sheep BMmononuclear cells (BMMNC)were isolated from the BM
of adult (2–3 years old) ewes by Ficoll density gradient (Histopaque
1077; Sigma) centrifugation, according to approved Institutional966 Stem Cell Reports j Vol. 6 j 957–969 j June 14, 2016Animal Care and Use Committee (IACUC) guidelines. Two
different stromal cell populations were isolated, one with mesen-
chymal progenitor cell activity (CD146++) and another with sinu-
soidal endothelial progenitor characteristics (CD146+++). Details
about isolation and culture of these cells are provided in Supple-
mental Experimental Procedures. Sheep CD34+ HSC were isolated
from BMMNC by positive selection using anti-sheep CD34 (Geno-
vac) and the MidiMACS system (Miltenyi Biotec) as previously
described (Porada et al., 2008).
Characterization of CD146++ or CD146+++ Cells by
Immunocytochemistry and Tube-Formation Assay
To better characterize cell phenotype and functionality, we
performed immunocytochemistry and tube-formation assays as
detailed in Supplemental Experimental Procedures. For determina-
tion of whether CD146++ cells fulfilled the criteria of mesen-
chymal progenitors, these cells were induced to differentiate into
adipocytes and osteocytes as previously described (Soland et al.,
2012) and as detailed in Supplemental Experimental Procedures.
Lentiviral Vector Transduction
To facilitate tracking post-transplantation, we transduced
CD146+++ or CD146++ cells with the LVmKate-2 lentivector, and
CD34+ HSCs with the Lv105-eGFP lentivector (both from Capital
Biosciences), as detailed in Supplemental Experimental Proce-
dures. CFU assays were performed to confirm preservation of
hematopoietic engraftment capability (Wiley and Yeager, 1991).
In Utero Transplantation and Tissue Collection
A total of 33 animals were used in these studies. Fetal sheep were
injected intraperitoneally at 60–65 gestational days, which corre-
sponds to 16–17 weeks of gestation in humans, by ultrasound-
guided transabdominal percutaneous injection as described by
Chamberlain et al. (2007), and in accordance with IACUC guide-
lines, with different subsets of cells derived from the same donor:
(1) CD146++ and HSC simultaneously (n = 14); (2) CD146++
followed by HSC 3 days later (n = 4); (3) CD146+++ and HSC simul-
taneously (n = 5); (4) CD146+++, followed by HSC 3 days
later (n = 4); or (5) HSC alone (n = 4). CD146++ cells, CD146+++
cells, and HSC were administered at a dose of 2.5 3 106/kg, 7.1 3
106/kg, and 2.1 3 106/kg, respectively. Non-transplanted animals
(n = 2) were used as controls.
Colony-Forming Cell Assays
BMaspirates were collected from the iliac crest at the time of eutha-
nasia. Methylcellulose colony assays were performed by plating
10,000 BMMNC inMethoCult GF H4330 (StemCell Technologies)
supplemented with PHA-stimulated sheep leukocyte-conditioned
medium (PHA-LCM) (5% v/v), as previously described (Porada
et al., 2008). The percentage of GFP+ colonies was calculated by
dividing the number of GFP+ colonies by the total number of
GFP+ and GFP colonies.
Flow Cytometric Analysis
Flow cytometric analysis was performed to assess levels of donor
hematopoietic cell engraftment. For evaluation of the percentage
of donor-derived GFP+ CD45+ cells within the PB and BM, cells
were stained with RPE-conjugated anti-ovine CD45 (Serotec;
MCA2220PE) and fluorescein isothiocyanate (FITC)-conjugated
ANTI-GFP antibody (Abcam; ab66180), and analyzed on a
FACSCalibur (Becton Dickinson Immunocytometry Systems).
Negative controls included: mouse immunoglobulin 1 (IgG1)
RPE isotype negative control (Serotec; MCA928RPE) and rabbit
IgG FITC isotype control (Abcam; ab37406).Immunohistochemistry
Long bones were collected, processed, and stained with antibodies
to the lentivector-encoded reporter genes, cell-specific markers,
and Ki67, as detailed in Supplemental Experimental Procedures,
to examine the localization of the transplanted cells within the
fetal sheep BM, levels of HSC engraftment, and proliferative status.Statistical Analysis
All data are presented as mean ± SEM. We used GraphPad Prism 6
(GraphPad Software) for statistical analysis, and ordinary one-way
ANOVA followed by a Holm-Sidak multiple comparisons test with
a singled pooled variance. Spearman’s correlation tests were
applied to evaluate correlations. For all analyses, p % 0.05 was
considered to be statistically significant.
SUPPLEMENTAL INFORMATION
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Procedures and two figures and can be found with this article on-
line at http://dx.doi.org/10.1016/j.stemcr.2016.05.009.
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